EXPERT-C: A randomized, phase II European multicenter trial of neoadjuvant capecitabine plus oxaliplatin chemotherapy (CAPOX) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined, high-risk rectal cancer.
A. Dewdney
No relevant relationships to disclose
J. Capdevila
Honoraria - Roche
B. Glimelius
Research Funding - Merck
A. Cervantes
Consultant or Advisory Role - Merck Serono (U)
Honoraria - Merck Serono; Roche
D. M. Tait
No relevant relationships to disclose
G. Brown
No relevant relationships to disclose
A. Wotherspoon
No relevant relationships to disclose
D. Gonzalez de Castro
No relevant relationships to disclose
Y. J. Chua
Honoraria - Roche
R. Wong
Consultant or Advisory Role - Roche (U)
Honoraria - Roche
Y. Barbachano
No relevant relationships to disclose
J. R. Oates
No relevant relationships to disclose
I. Chau
Consultant or Advisory Role - Merck; Roche
Honoraria - Roche
Research Funding - Merck Serono; Roche; Sanofi
D. Cunningham
Consultant or Advisory Role - Amgen (U); AstraZeneca (U); Roche (U); Sanofi (U)
Research Funding - Amgen; Merck Serono; Roche; Sanofi